On Tuesday, researchers identified a low-cost and readily accessible painkiller that has been shown to exhibit notable anti-cancer properties.
According to Business Standard, it’s called diclofenac, and it’s a well known, cost-effective pain killer. Research indicates that it has the potential to reduce the risk of a post-surgical spread of cancer, which has huge implications for the fight against cancer.
Taking the drug in combination with other cancer treatments, like chemotherapy and radiotherapy, has been shown to improve effectiveness in the overall treatment of cancer. The data from the study comes from clinical studies which tested the impact on cancer treatments that drug diclofenac can have.
Study author Pan Pantziarka, a member of the Repurposing Drugs in Oncology (ReDO) project, emphasized the importance of drug trials for painkillers and other drugs in an oncological sense.
“We can see that these drugs re multi-targeted agents with interesting and useful effects on multiple pathways of interest in oncology,” he said.
The study, which was part of the ReDO project, appeared in the journal ecancermedicalscience.
Pantziarka’s ReDO project represents an international collaboration between the Anticancer Fund, Belgium, and US based organization GlobalCures.
Leave a Reply